Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

134.69 -6.18 (-4.39%)
Streaming Delayed Price Updated: 10:55 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Smart Money Is Betting Big In NVO Options
Via Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries 
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Should Quality Investors Include NYSE:NVO in Their Portfolio?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing? 
Via Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and... 
Via Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days. 
Via The Motley Fool
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal... 
Via Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
This company is serious about maintaining its leadership. 
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Both of these businesses are finding traction in a pair of major markets. 
Via The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug. 
Via Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed. 
Via Benzinga
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations. 
Via InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
While people tend to be too cool for school regarding groupthink, these popular stocks among retail investors could change perceptions. 
Via InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
This is a stock you shouldn't hesitate to buy on the dip. 
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart. 
Via Benzinga
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.